Jelena Pesic1, Frank Risse1,
Simon Young2, Jim Britt2, Ignacio Rodriguez3,
Lars E. Olsson1
1DECS Imaging and Antibodies,
AstraZeneca R&D, Mlndal, Sweden; 2Bioscience, AstraZeneca
R&D, Charnwood, United Kingdom; 3Instituto de Estudios
Biofuncionales, Universidad Complutense, Madrid, Spain
HP
3He ADC imaging was used to assess the effect of a glucocorticoid
budesonide on inflammation in ovalbumin challenged rats. Four groups of
animals were investigated: controls, vehicle treated, low and high dose
budesonide treated. The ADC was significantly smaller in the vehicle group,
indicating reduced airspace in the alveoli, possibly due to plasma leakage
into the alveoli. Treatment with budesonide decreased inflammation as shown
by significantly reduced eosinophil counts and higher ADC values than in the
vehicle group.